338 related articles for article (PubMed ID: 37495610)
1. TIGIT, a novel immune checkpoint therapy for melanoma.
Tang W; Chen J; Ji T; Cong X
Cell Death Dis; 2023 Jul; 14(7):466. PubMed ID: 37495610
[TBL] [Abstract][Full Text] [Related]
2. Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.
Chu X; Tian W; Wang Z; Zhang J; Zhou R
Mol Cancer; 2023 Jun; 22(1):93. PubMed ID: 37291608
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
[TBL] [Abstract][Full Text] [Related]
4. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Kawaguchi K; Toda Y; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2425-2436. PubMed ID: 35737088
[TBL] [Abstract][Full Text] [Related]
6. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.
Yoo KJ; Johannes K; González LE; Patel A; Shuptrine CW; Opheim Z; Lenz K; Campbell K; Nguyen TA; Miriyala J; Smith C; McGuire A; Tsai YH; Rangwala F; de Silva S; Schreiber TH; Fromm G
J Immunol; 2022 Aug; 209(3):510-525. PubMed ID: 35817517
[TBL] [Abstract][Full Text] [Related]
7. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
Cai L; Li Y; Tan J; Xu L; Li Y
J Hematol Oncol; 2023 Sep; 16(1):101. PubMed ID: 37670328
[TBL] [Abstract][Full Text] [Related]
8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
9. Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes.
Lee WJ; Lee YJ; Choi ME; Yun KA; Won CH; Lee MW; Choi JH; Chang SE
J Am Acad Dermatol; 2019 Jul; 81(1):219-227. PubMed ID: 30880064
[TBL] [Abstract][Full Text] [Related]
10. Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma.
Wang P; Chen Y; Long Q; Li Q; Tian J; Liu T; Wu Y; Ding Z
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625514
[TBL] [Abstract][Full Text] [Related]
11. LAG3 and TIGIT Expression on Tumor-Infiltrating Lymphocytes in Cutaneous Melanoma.
Naimy S; Bzorek M; Eriksen JO; Løvendorf MB; Litman T; Dyring-Andersen B; Gjerdrum LMR
Dermatology; 2024; 240(1):156-163. PubMed ID: 37952520
[TBL] [Abstract][Full Text] [Related]
12. [Research Progress of Immune Checkpoint TIGIT in Lung Cancer Immunotherapy].
Wu J; Ren D; Bi H; Yi B; Wang H
Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):819-827. PubMed ID: 36419396
[TBL] [Abstract][Full Text] [Related]
13. Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity.
Zhong Z; Zhang M; Ning Y; Mao G; Li X; Deng Q; Chen X; Zuo D; Zhao X; Xie E; Wang H; Guo L; Li B; Xiao K; He X
Sci Rep; 2022 Oct; 12(1):18011. PubMed ID: 36289396
[TBL] [Abstract][Full Text] [Related]
14. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY; Tawbi HA
Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
[TBL] [Abstract][Full Text] [Related]
15. TIGIT in cancer immunotherapy.
Chauvin JM; Zarour HM
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900861
[TBL] [Abstract][Full Text] [Related]
16. Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma.
Vanella V; Festino L; Vitale MG; Alfano B; Ascierto PA
Expert Opin Emerg Drugs; 2021 Jun; 26(2):79-92. PubMed ID: 33686894
[TBL] [Abstract][Full Text] [Related]
17. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.
Grapin M; Richard C; Limagne E; Boidot R; Morgand V; Bertaut A; Derangere V; Laurent PA; Thibaudin M; Fumet JD; Crehange G; Ghiringhelli F; Mirjolet C
J Immunother Cancer; 2019 Jun; 7(1):160. PubMed ID: 31238970
[TBL] [Abstract][Full Text] [Related]
18. TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.
Yeo J; Ko M; Lee DH; Park Y; Jin HS
Pharmaceuticals (Basel); 2021 Feb; 14(3):. PubMed ID: 33670993
[TBL] [Abstract][Full Text] [Related]
19. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
Front Immunol; 2021; 12():637146. PubMed ID: 34025646
[TBL] [Abstract][Full Text] [Related]
20. TIGIT
Tsakmaklis A; Farowski F; Zenner R; Lesker TR; Strowig T; Schlößer H; Lehmann J; von Bergwelt-Baildon M; Mauch C; Schlaak M; Knuever J; Schweinsberg V; Heinzerling LM; Vehreschild MJGT
BMC Cancer; 2023 Nov; 23(1):1160. PubMed ID: 38017389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
